Establishment and characterization of rat portal myofibroblast cell lines

Michel Fausther1, Jessica R Goree1, Élise G Lavoie1

  • 1Division of Gastroenterology & Hepatology, University of Arkansas for Medical Sciences, Little Rock, AR, United States of America; Research Service, Central Arkansas VA Healthcare System, Little Rock, AR, United States of America.

Plos One
|March 31, 2015
PubMed

Insights

Researchers developed two new rat portal myofibroblast cell lines, RGF and RGF-N2, to study liver fibrosis. These cell lines are vital tools for understanding the role of portal fibroblasts in liver disease progression.

Area of Science:

  • Cell Biology
  • Hepatology
  • Fibrosis Research

Background:

  • Liver fibrosis involves scar-forming myofibroblasts, primarily activated hepatic stellate cells (HSC) and portal fibroblasts (PF).
  • Portal fibroblasts (PF) are understudied due to challenges in isolation and lack of established cell lines.
  • Understanding PF is crucial for developing targeted therapies for liver fibrosis.

Purpose of the Study:

  • To generate and characterize novel immortalized rat portal myofibroblast cell lines.
  • To establish reliable in vitro models for studying PF function in liver fibrosis.
  • To investigate the potential of these cell lines in understanding cholangiocarcinoma progression.

Main Methods:

  • Primary rat portal fibroblasts (PF) were cultured, activated, and immortalized using SV40.
  • The RGF-N2 cell line was specifically generated from Ntpdase2/Cd39l1-sorted primary PF.
  • Functional characterization involved RT-PCR, immunofluorescence, immunoblotting, and proliferation assays.

Main Results:

  • The RGF and RGF-N2 cell lines express key myofibroblast and PF-specific markers (e.g., alpha smooth muscle actin, elastin, Ntpdase2/Cd39l1) and are readily transfectable.
  • These cell lines are negative for HSC-specific markers (desmin, lecithin retinol acyltransferase).
  • RGF and RGF-N2 cells demonstrated the ability to inhibit cholangiocarcinoma cell growth in co-culture.

Conclusions:

  • The established RGF and RGF-N2 cell lines serve as valuable in vitro models for portal (myo)fibroblast research.
  • These models will facilitate functional studies on the contribution of PF to liver fibrosis progression.
  • The cell lines offer a platform for investigating therapeutic strategies targeting PF in liver disease.

Related Concept Videos